TL1A, also known as TNFSF15, is a tumor necrosis factor (TNF) family member cytokine predominantly expressed by monocytes, macrophages, dendritic cells (DCs), synovial fibroblasts, and endothelial cells. Its cognate cell surface receptor, DR3 (TNFRSF25), is primarily expressed on T cells, where TL1A signaling co-stimulates T-cell activation and drives pro-inflammatory cytokine production. Dysregulation of the TL1A/DR3 pathway is strongly linked to human inflammatory bowel disease (IBD), Crohn's disease, and various autoimmune pathologies, making it a high-value target for therapeutic antibody screening and biomarker validation.

Product Features & Specifications

• Expression System: Engineered and expressed in an optimized E. coli bacterial system.
• Construct Design: Features a DNA sequence encoding human TL1A (Ser57-Leu251) fused with a C-terminal AviTag™ peptide sequence and a C-terminal His-tag.
• Precision Biotinylation: Site-specifically biotinylated at the C-terminal AviTag™ using BirA enzyme, ensuring uniform molecular orientation and maximum ligand binding capacity.
• Molecular Mass: Resolves at approximately ~25 kDa (monomer) under reducing conditions on SDS-PAGE.
• High Purity: Verified at >90% purity by Coomassie blue staining.
• Storage Buffer: Supplied in 20 mM Phosphate buffer, pH 7.4, 120 mM NaCl, 5 mM 2-mercaptoethanol, and 10% glycerol for optimal long-term stability.

Validated Assay Applications

This precision C-terminal biotinylated human TL1A protein is specifically optimized for high-sensitivity binding assays, surface plasmon resonance (SPR), bio-layer interferometry (BLI), AlphaLISA, and streptavidin-coated plate ELISA high-throughput screening of neutralizing anti-TL1A antibodies.

Catalog Number: TL1A-B-C-301 | This product is intended for laboratory research use only (ROU).